Skip to main content

Table 1 Expression of LINC01133 in cell lines

From: A review on the role of LINC01133 in cancers

Tumor/ disorder type

Interacting molecules and pathways

Cell lines

Function

References

Gastric cancer

miR-106a-3p, APC, Wnt/β-catenin pathway

SUN-216, BGC-823, AGS, BGC-803, NUGC4, MKN74, MKN45, SGC-7901, HGC-27 and GES-1

∆ LINC01133: ↑ proliferation, ↑ migration, ↑ EMT process

[21]

miR-576-5p, SST

GC cells

↑ LINC01133: ↓ malignant phenotypes

[22]

Epithelial ovarian cancer

miR-495-3p, TPD52

SKOV3, A2780, IOSE8

↑ LINC01133: ↑ migration, ↑ invasion

[14]

Ovarian cancer

miR-205, LRRK2

IOSE80, SKOV-3, HO-8910, and OVCAR-8

↑ LINC01133: ↓ proliferation, ↓ migration, ↓ invasion

[15]

Hepatocellular carcinoma

PI3K/AKT signaling pathway

HepG2, Hep3B, MHCC-97 L, SK-Hep-1, and MHCC-97 H, HL-7702

∆ LINC01133: ↓ proliferation, ↓ migration, ↓ invasion, ↓ colony formation, ↑ apoptosis, ↑ G1 phase arrest

[23]

miR-199a-5p, SNAI1, EMT, ANXA2/STAT3/cyclin D1 signaling

MHCC97L, MHCC97H, and HCCLM3, Hep3B, HepG2, PLC/PRF/5, and Huh7

∆ LINC01133: ↓ proliferation, ↓ migration, ↓ invasion, ↓ colony formation

↑ LINC01133: ↑ proliferation, ↑ migration, ↑ invasion, ↑ colony formation, ↑ EMT process

[19]

Cervical cancer

miR-4784, AHDC1

NC104, Hela, ME-180, C33A and MS751

∆ LINC01133: ↓ proliferation, migration, ↓ invasion, ↓ EMT process

[24]

miR-30a-5p, FOXD1

HeLa, HT-3, C33A, SiHa

↑ LINC01133: ↑ proliferation, ↑ migration, ↑ invasion, ↓ apoptosis

[16]

Breast cancer

EZH2, SOX4

MDA-MB‐231, SKBR‐3, MDA‐MB‐468, ZR‐75‐1, BT474, MCF‐7 and T47D, MCF‐10 A

∆ LINC01133: ↑ viability, ↑ migration, ↑ invasion

↑ LINC01133: ↓ viability, ↓ migration, ↓ invasion

[25]

miR-199a, FOXP2,

KLF4 (Pluripotency Master Regulator)

DA-MB-231, MDA-MB-468, HCC1937, T47D, MCF7, ZR-75-1, BT-20, HCC1143, BT549, and Hs578T, HCC70, 4T1, and MCF10A

↑ LINC01133: ↑ SC-Like Traits in TNBC Cells

[17]

Nasopharyngeal carcinoma

YBX1

NP69, CNE-1, CNE-2, 5-8 F, 6-10B, and SUNE-1

∆ LINC01133: ↑ proliferation, ↑ migration, ↑ invasion, ↑ colony formation, ↑ EMT process

↑ LINC01133: ↓ proliferation, ↓ migration, ↓ invasion, ↓ colony formation, ↓ EMT process

[26]

Renal cell carcinoma

miR-30b-5p, Rab3D

HKC, ACHIN, A498, SN12PM6, and 786-O

∆ LINC01133: ↓ proliferation, ↓ migration, ↓ invasion

[27]

Endometrial carcinoma

 

Ishikawa and HEC-1-A cells

∆ LINC01133: ↓ proliferation, migration, ↓ invasion

[28]

Pancreatic cancer

C/EBPβ, CCNG1

BXPC3, CFPAC1, PANC1, and SW1990, CAPAN-2

∆ LINC01133: ↓ proliferation

[29]

DKK1, Wnt signaling pathway

SW1990, Capan1, AsPc1, PANC − 1, BxPC − 3, and HPDE

↑ LINC01133: ↑ growth, ↑ proliferation, ↑ migration, ↑ metastasis, and ↑ invasion

[18]

miR-216a -5p,

TPT1, mTORC1 pathway

SW1990, PANC1, Capan-2, BxPC-3, and HPDE6

↑ miR-216a -5p

(a target of LINC01133): ↓ proliferation, ↓ colony formation, ↑ cell cycle arrest

∆ LINC01133: ↓ proliferation, migration, ↓ invasion

[30]

Periostin, EZH2, AXIN2, Wnt/β-catenin pathway

CFPAC-1, AsPC-1, Panc-1, SW1990, HPDE, human PSCs

∆ LINC01133: ↓ proliferation, ↓ migration, ↓ invasion, ↑ apoptosis

↑ LINC01133: ↑ proliferation, ↑ migration, ↑ invasion, ↓ apoptosis

Periostin up-regulated LINC01133.

[31]

Oral squamous cell carcinoma

GDF15

NOK, CAL27, HN4, and 293FT

∆ LINC01133: did not affect proliferation, ↑ migration, ↑ invasion

[32]

Osteosarcoma

miR-422a

MG63, Saos-2, HOS, U2-OS, NHOst, and HEK-293

∆ LINC01133: ↓ proliferation, ↓ migration, ↓ invasion

[33]

Colorectal cancer

TGF-β signaling pathway, SRSF6

HT29, HCT8, LS513, SW620, and HCT11

∆ LINC01133: ↑ EMT process, ↑ metastasis

TGF-β signaling pathway inhibited LINC01133.

[34]

Lung cancer

KLF2, P21 and E-cadherin, EZH2 and LSD1

PC9, SPC-A1, NCI-H1975, H1299, and A549, H520, H1703, and SK-MES-1

∆ LINC01133: ↓ proliferation, ↓ migration, ↓ invasion, ↑ apoptosis

[20]

 

H1703

∆ LINC01133: ↓ migration, ↓ invasion

[35]

Bladder cancer

Wnt signaling pathway

V-HUC‐1, T24 and J82

↑ LINC01133: ↓ proliferation, ↓ migration, ↓ invasion

[36]

  1. ∆: knock-down or deletion, SC: stem cell, TNBC: triple-negative breast cancers